Tenet Healthcare (THC) Expected to Announce Quarterly Earnings on Tuesday

Tenet Healthcare (NYSE:THC - Get Free Report) will likely be issuing its Q1 2025 quarterly earnings data before the market opens on Tuesday, April 29th. Analysts expect Tenet Healthcare to post earnings of $3.10 per share and revenue of $5.15 billion for the quarter. Tenet Healthcare has set its FY 2025 guidance at 11.740-12.840 EPS.

Tenet Healthcare (NYSE:THC - Get Free Report) last issued its quarterly earnings results on Wednesday, February 12th. The company reported $3.44 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.95 by $0.49. Tenet Healthcare had a net margin of 15.48% and a return on equity of 21.88%. On average, analysts expect Tenet Healthcare to post $12 EPS for the current fiscal year and $13 EPS for the next fiscal year.

Tenet Healthcare Stock Down 1.8 %

Tenet Healthcare stock traded down $2.25 during mid-day trading on Friday, reaching $121.99. 1,181,748 shares of the company's stock were exchanged, compared to its average volume of 1,513,890. The company has a fifty day moving average of $126.77 and a 200-day moving average of $137.22. The company has a market cap of $11.51 billion, a P/E ratio of 3.78, a P/E/G ratio of 1.02 and a beta of 1.77. The company has a quick ratio of 1.70, a current ratio of 1.78 and a debt-to-equity ratio of 2.25. Tenet Healthcare has a twelve month low of $92.01 and a twelve month high of $171.20.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the stock. KeyCorp reduced their price objective on shares of Tenet Healthcare from $200.00 to $185.00 and set an "overweight" rating on the stock in a report on Tuesday, January 7th. TD Cowen initiated coverage on Tenet Healthcare in a report on Wednesday, February 26th. They issued a "buy" rating and a $175.00 price target for the company. Cantor Fitzgerald restated an "overweight" rating and set a $177.00 price objective on shares of Tenet Healthcare in a research report on Thursday, February 13th. Guggenheim assumed coverage on shares of Tenet Healthcare in a research report on Wednesday, April 9th. They issued a "buy" rating and a $165.00 target price on the stock. Finally, Barclays decreased their price objective on shares of Tenet Healthcare from $190.00 to $161.00 and set an "overweight" rating for the company in a research note on Thursday, February 13th. Five research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company's stock. Based on data from MarketBeat, Tenet Healthcare currently has an average rating of "Moderate Buy" and a consensus target price of $165.44.

Insider Activity

In other news, Director J Robert Kerrey sold 9,525 shares of the firm's stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $125.43, for a total value of $1,194,720.75. Following the transaction, the director now owns 27,378 shares of the company's stock, valued at approximately $3,434,022.54. This trade represents a 25.81 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 0.81% of the company's stock.

About Tenet Healthcare

Tenet Healthcare Corporation operates as a diversified healthcare services company in the United States. The company operates through two segments: Hospital Operations and Services, and Ambulatory Care. Its general hospitals offer acute care services, operating and recovery rooms, radiology and respiratory therapy services, clinical laboratories, and pharmacies.